Difference between revisions of "Light-chain (AL) amyloidosis"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replace - ", et al. " to " et al. ")
m
Line 10: Line 10:
 
CRD: '''<u>Cy</u>'''clophosphamide, '''<u>R</u>'''evlimid, '''<u>D</u>'''examethasone
 
CRD: '''<u>Cy</u>'''clophosphamide, '''<u>R</u>'''evlimid, '''<u>D</u>'''examethasone
  
−
===Regimen===
+
===Regimen, Kumar et al. 2012===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 22: Line 22:
 
*[[Lenalidomide (Revlimid)]] 15 mg PO once daily on days 1 to 21
 
*[[Lenalidomide (Revlimid)]] 15 mg PO once daily on days 1 to 21
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1, 8, 15, 22
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1, 8, 15, 22
−
**In Palladini et al. 2013 only, patients who retained over 3% body weight despite "optimal diuretic use" received [[Dexamethasone (Decadron)]] 20 mg PO once per week
 
  
−
'''28-day cycles x up to 9 cycles or 2 years, depending on reference'''
+
Supportive medications:
 +
*[[Aspirin]] 81, 100, or 325 mg PO once daily for thromboprophylaxis
 +
*Patients with previous thrombotic histories or who were considered to be higher thrombotic risks were recommended to receive low molecular weight heparin or [[Warfarin (Coumadin)]]
 +
*"Routine antibiotic, antiviral, or antifungal prophylaxis was not mandated and left to the discretion of the treating physician."
  
−
Supportive medications (varies depending on reference):
+
'''28-day cycles x up to 2 years'''
−
*[[Aspirin]] 81, 100, or 325 mg PO once daily for thromboprophylaxis
 
−
*In Kumar et al. 2012, patients with previous thrombotic histories or who were considered to be higher thrombotic risks were recommended to receive low molecular weight heparin or [[Warfarin (Coumadin)]]
 
−
*Kumar et al. 2012: "Routine antibiotic, antiviral, or antifungal prophylaxis was not mandated and left to the discretion of the treating physician."
 
  
 
===References===
 
===References===
−
# Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24;119(21):4860-7. doi: 10.1182/blood-2012-01-407791. Epub 2012 Apr 13. [http://bloodjournal.hematologylibrary.org/content/119/21/4860.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22504925 PubMed]
+
# Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24;119(21):4860-7. Epub 2012 Apr 13. [http://bloodjournal.hematologylibrary.org/content/119/21/4860.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22504925 PubMed]
  
 
==CTD==
 
==CTD==
Line 38: Line 37:
  
 
===Regimen #1, Wechalekar et al. 2007===
 
===Regimen #1, Wechalekar et al. 2007===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 49: Line 48:
 
*[[Thalidomide (Thalomid)]] 100 mg PO once daily on days 1 to 21, then increased to 200 mg PO once daily on days 1 to 21 if well tolerated after 4 weeks
 
*[[Thalidomide (Thalomid)]] 100 mg PO once daily on days 1 to 21, then increased to 200 mg PO once daily on days 1 to 21 if well tolerated after 4 weeks
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1 to 4, 9 to 12
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1 to 4, 9 to 12
−
 
−
'''21-day cycles, "given until a stable clonal response was achieved on consecutive samples at least 4 weeks apart" or until confirmed lack of response'''
 
  
 
Supportive medications:
 
Supportive medications:
 
*"Antimicrobial and thromboprophylaxis were given according to local protocol"; no routine thromboprophylaxis
 
*"Antimicrobial and thromboprophylaxis were given according to local protocol"; no routine thromboprophylaxis
 +
 +
'''21-day cycles, "given until a stable clonal response was achieved on consecutive samples at least 4 weeks apart" or until confirmed lack of response'''
  
 
===Regimen #2, Wechalekar et al. 2007 - risk attenuated regimen===
 
===Regimen #2, Wechalekar et al. 2007 - risk attenuated regimen===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 68: Line 67:
 
*[[Thalidomide (Thalomid)]] 50 mg PO once daily on days 1 to 28, increased by 50 mg every 4 weeks as tolerated to a maximum dose of 200 mg PO once daily
 
*[[Thalidomide (Thalomid)]] 50 mg PO once daily on days 1 to 28, increased by 50 mg every 4 weeks as tolerated to a maximum dose of 200 mg PO once daily
 
*[[Dexamethasone (Decadron)]] 20 mg PO once daily on days 1 to 4, 15 to 18
 
*[[Dexamethasone (Decadron)]] 20 mg PO once daily on days 1 to 4, 15 to 18
−
 
−
'''28-day cycles, "given until a stable clonal response was achieved on consecutive samples at least 4 weeks apart" or until confirmed lack of response'''
 
  
 
Supportive medications:
 
Supportive medications:
 
*"Antimicrobial and thromboprophylaxis were given according to local protocol"; no routine thromboprophylaxis
 
*"Antimicrobial and thromboprophylaxis were given according to local protocol"; no routine thromboprophylaxis
 +
 +
'''28-day cycles, "given until a stable clonal response was achieved on consecutive samples at least 4 weeks apart" or until confirmed lack of response'''
  
 
===References===
 
===References===
Line 81: Line 80:
  
 
===Regimen===
 
===Regimen===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#ff0000;
 
style="background:#ff0000;
Line 92: Line 91:
 
*[[Bortezomib (Velcade)]] 1.5 mg/m2 (route not specified) once per week OR 1.3 mg/m2 on days 1, 4, 8, 11
 
*[[Bortezomib (Velcade)]] 1.5 mg/m2 (route not specified) once per week OR 1.3 mg/m2 on days 1, 4, 8, 11
 
*[[Dexamethasone (Decadron)]] 40 mg (route not specified) once per week
 
*[[Dexamethasone (Decadron)]] 40 mg (route not specified) once per week
−
 
−
'''28-day cycles x 2-6 cycles'''
 
  
 
Supportive medications:
 
Supportive medications:
 
*"Antiviral prophylaxis"
 
*"Antiviral prophylaxis"
 +
 +
'''28-day cycles x 2 to 6 cycles'''
  
 
===References===
 
===References===
−
# Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012 May 10;119(19):4391-4. doi: 10.1182/blood-2011-11-390930. Epub 2012 Feb 13. [http://bloodjournal.hematologylibrary.org/content/119/19/4391.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22331188 PubMed]
+
# Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012 May 10;119(19):4391-4. Epub 2012 Feb 13. [http://bloodjournal.hematologylibrary.org/content/119/19/4391.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22331188 PubMed]
  
−
==Lenalidomide & Dexamethasone==
+
==Lenalidomide +/- Dexamethasone==
  
 
===Regimen #1, Sanchorwala et al. 2007===
 
===Regimen #1, Sanchorwala et al. 2007===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 111: Line 110:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
 +
 +
''The trial used an initial dose of lenalidomide of 25 mg PO once daily, but it was reduced to 15 mg because 25 mg was poorly tolerated.''
  
 
*[[Lenalidomide (Revlimid)]] 15 mg PO once daily on days 1 to 21
 
*[[Lenalidomide (Revlimid)]] 15 mg PO once daily on days 1 to 21
−
**The trial used an initial dose of 25 mg PO once daily, but it was reduced to 15 mg because 25 mg was poorly tolerated.
 
  
−
'''28-day cycles; if no response after 3 cycles of therapy, then patients would receive:'''
+
'''28-day cycles; if no response after 3 cycles of therapy, then patients would also receive:'''
  
−
*[[Lenalidomide (Revlimid)]] 15 mg PO once daily on days 1 to 21, given every cycle
 
 
*[[Dexamethasone (Decadron)]] 10 to 20 mg PO once daily on days 1 to 4, 9 to 12, 17 to 20, given every other cycle
 
*[[Dexamethasone (Decadron)]] 10 to 20 mg PO once daily on days 1 to 4, 9 to 12, 17 to 20, given every other cycle
−
 
−
'''28-day cycles, given until progression of disease or unacceptable toxicity'''
 
  
 
Supportive medications:
 
Supportive medications:
 
*[[Aspirin]] 81 or 325 mg (physician discretion) PO once daily as prophylaxis
 
*[[Aspirin]] 81 or 325 mg (physician discretion) PO once daily as prophylaxis
 
*Proton pump inhibitor used for patients receiving dexamethasone
 
*Proton pump inhibitor used for patients receiving dexamethasone
 +
 +
'''28-day cycles, given until progression of disease or unacceptable toxicity'''
  
 
===Regimen #2, Dispenzieri et al. 2007===
 
===Regimen #2, Dispenzieri et al. 2007===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 137: Line 136:
 
*[[Lenalidomide (Revlimid)]] 25 mg PO once daily on days 1 to 21
 
*[[Lenalidomide (Revlimid)]] 25 mg PO once daily on days 1 to 21
  
−
'''28-day cycles; if no response after 3 cycles of therapy, then patients would receive:'''
+
'''28-day cycles; if no response after 3 cycles of therapy, then patients would also receive:'''
  
−
*[[Lenalidomide (Revlimid)]] 25 mg PO once daily on days 1 to 21
 
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1 to 4, 15 to 18
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1 to 4, 15 to 18
  
Line 152: Line 150:
 
==Melphalan & Dexamethasone==
 
==Melphalan & Dexamethasone==
 
===Regimen===
 
===Regimen===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 162: Line 160:
 
*[[Melphalan (Alkeran)]] 0.22 mg/kg PO once daily on days 1 to 4
 
*[[Melphalan (Alkeran)]] 0.22 mg/kg PO once daily on days 1 to 4
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1 to 4
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1 to 4
 +
 +
Supportive medications:
 +
*[[Omeprazole (Prilosec)]] 20 mg PO once daily on days 1 to 10
 +
*[[Ciprofloxacin (Cipro)]] 250 mg PO BID on days 1 to 10
 +
*[[Itraconazole (Sporanox)]] 100 mg PO once daily on days 1 to 10
  
 
'''28-day cycles x up to 9 cycles'''
 
'''28-day cycles x up to 9 cycles'''
−
 
−
Supportive medications:
 
−
*Omeprazole (Prilosec) 20 mg PO once daily on days 1 to 10
 
−
*Ciprofloxacin (Cipro) 250 mg PO BID on days 1 to 10
 
−
*Itraconazole (Sporanox) 100 mg PO once daily on days 1 to 10
 
  
 
===References===
 
===References===
 
# Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, Rustichelli R, Virga G, Merlini G. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004 Apr 15;103(8):2936-8. Epub 2003 Dec 18. [http://bloodjournal.hematologylibrary.org/content/103/8/2936.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15070667 PubMed]
 
# Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, Rustichelli R, Virga G, Merlini G. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004 Apr 15;103(8):2936-8. Epub 2003 Dec 18. [http://bloodjournal.hematologylibrary.org/content/103/8/2936.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15070667 PubMed]
−
# '''Retrospective:''' Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013 Apr 25;121(17):3420-7. doi: 10.1182/blood-2012-12-473066. Epub 2013 Mar 11. [http://bloodjournal.hematologylibrary.org/content/121/17/3420.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/23479568 PubMed] ''Melphalan & dexamethasone (MDex) only regimen explicitly mentioned in cohort.  Others included thalidomide combination, bortezomib combination, and lenalidomide combination.''
+
# '''Retrospective:''' Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013 Apr 25;121(17):3420-7. Epub 2013 Mar 11. [http://bloodjournal.hematologylibrary.org/content/121/17/3420.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/23479568 PubMed] ''Melphalan & dexamethasone (MDex) only regimen explicitly mentioned in cohort.  Others included thalidomide combination, bortezomib combination, and lenalidomide combination.''
  
 
==MRD==
 
==MRD==
Line 178: Line 176:
  
 
===Regimen #1, Sanchorwala et al. 2012===
 
===Regimen #1, Sanchorwala et al. 2012===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#ff0000;
 
style="background:#ff0000;
Line 190: Line 188:
 
*[[Lenalidomide (Revlimid)]] 10 mg PO once daily on days 1 to 21
 
*[[Lenalidomide (Revlimid)]] 10 mg PO once daily on days 1 to 21
 
*[[Dexamethasone (Decadron)]] 40 mg PO once per week
 
*[[Dexamethasone (Decadron)]] 40 mg PO once per week
 +
 +
Supportive medications:
 +
*[[Aspirin]] 325 mg PO once daily to decrease risk of [[Lenalidomide (Revlimid)]]-associated venous thromboembolism (VTE)
 +
*Proton pump inhibitor to decrease risk of gastritis from [[Dexamethasone (Decadron)]]
  
 
'''28-day cycles x 12 cycles, until progression of disease, or unacceptable toxicity'''
 
'''28-day cycles x 12 cycles, until progression of disease, or unacceptable toxicity'''
  
−
Supportive medications:
+
===Regimen #2, Moreau et al. 2010===
−
*[[Aspirin]] 325 mg PO once daily to decrease risk of lenalidomide-associated venous thromboembolism (VTE)
 
−
*Proton pump inhibitor to decrease risk of gastritis from dexamethasone
 
  
−
===Regimen #2, Moreau et al. 2010===
 
−
Level of Evidence:
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 209: Line 207:
  
 
===References===
 
===References===
−
# Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, Salles G, Leblond V, Roussel M, Alakl M, Hermine O, Planche L, Harousseau JL, Fermand JP. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010 Dec 2;116(23):4777-82. doi: 10.1182/blood-2010-07-294405. Epub 2010
+
# Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, Salles G, Leblond V, Roussel M, Alakl M, Hermine O, Planche L, Harousseau JL, Fermand JP. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010 Dec 2;116(23):4777-82. Epub 2010 Aug 19. [http://bloodjournal.hematologylibrary.org/content/116/23/4777.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/20724537 PubMed]
−
Aug 19. [http://bloodjournal.hematologylibrary.org/content/116/23/4777.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/20724537 PubMed]
+
# Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica. 2013 May;98(5):789-92. Epub 2012 Nov 9.  [http://www.haematologica.org/content/early/2012/10/29/haematol.2012.075192.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23144200 PubMed]
−
# Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica. 2013 May;98(5):789-92. doi: 10.3324/haematol.2012.075192. Epub 2012 Nov 9.  [http://www.haematologica.org/content/early/2012/10/29/haematol.2012.075192.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23144200 PubMed]
 
  
 
==RdC==
 
==RdC==
Line 217: Line 214:
  
 
===Regimen===
 
===Regimen===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 227: Line 224:
 
''This was the highest dose level tested in Kastritis et al. 2012, which had no dose-limiting toxicities.''
 
''This was the highest dose level tested in Kastritis et al. 2012, which had no dose-limiting toxicities.''
 
*[[Lenalidomide (Revlimid)]] 15 mg PO once daily on days 1 to 21
 
*[[Lenalidomide (Revlimid)]] 15 mg PO once daily on days 1 to 21
 +
*[[Dexamethasone (Decadron)]] 20 mg PO once daily on days 1 to 4
 
*[[Cyclophosphamide (Cytoxan)]] 100 mg PO once daily on days 1 to 10
 
*[[Cyclophosphamide (Cytoxan)]] 100 mg PO once daily on days 1 to 10
−
*[[Dexamethasone (Decadron)]] 20 mg PO once daily on days 1 to 4
 
−
 
−
'''28-day cycles x 12 cycles'''
 
  
 
Supportive medications:
 
Supportive medications:
Line 237: Line 232:
 
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim-sulfamethoxazole (Bactrim)]], dose and schedule not listed
 
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim-sulfamethoxazole (Bactrim)]], dose and schedule not listed
 
*[[Valacyclovir (Valtrex)]], dose and schedule not listed
 
*[[Valacyclovir (Valtrex)]], dose and schedule not listed
 +
 +
'''28-day cycles x 12 cycles'''
  
 
===References===
 
===References===
−
# Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S, Dimopoulos MA. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012 Jun 7;119(23):5384-90. doi: 10.1182/blood-2011-12-396903. Epub 2012 Apr 18. [http://bloodjournal.hematologylibrary.org/content/119/23/5384.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22517904 PubMed]
+
# Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S, Dimopoulos MA. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012 Jun 7;119(23):5384-90. Epub 2012 Apr 18. [http://bloodjournal.hematologylibrary.org/content/119/23/5384.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22517904 PubMed]
  
 
==VMD==
 
==VMD==
Line 245: Line 242:
  
 
===Regimen===
 
===Regimen===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 253: Line 250:
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
  
 +
*[[Bortezomib (Velcade)]] 1.3 mg/m2 IV once daily on days 1, 8, 15, 22, given first before [[Dexamethasone (Decadron)]]
 +
**Patients with peripheral neuropathy at baseline received [[Bortezomib (Velcade)]] 1.0 mg/m2 IV once daily on days 1, 8, 15, 22, given first before [[Dexamethasone (Decadron)]]
 
*[[Melphalan (Alkeran)]] 9 mg/m2 PO once daily on days 1 to 4
 
*[[Melphalan (Alkeran)]] 9 mg/m2 PO once daily on days 1 to 4
 
**Patients with serum creatinine >2.5 mg/dL received [[Melphalan (Alkeran)]] 6 mg/m2 PO once daily on days 1 to 4
 
**Patients with serum creatinine >2.5 mg/dL received [[Melphalan (Alkeran)]] 6 mg/m2 PO once daily on days 1 to 4
−
*[[Bortezomib (Velcade)]] 1.3 mg/m2 IV once daily on days 1, 8, 15, 22, given first before dexamethasone
 
−
**Patients with peripheral neuropathy at baseline received [[Bortezomib (Velcade)]] 1.0 mg/m2 IV once daily on days 1, 8, 15, 22, given first before dexamethasone
 
 
*[[Dexamethasone (Decadron)]] 40 mg PO/IV once daily on days 1, 8, 15, 22
 
*[[Dexamethasone (Decadron)]] 40 mg PO/IV once daily on days 1, 8, 15, 22
−
**Patients at least 70 years of age, with peripheral edema or congestive heart failure (CHF) received [[Dexamethasone (Decadron)]] 20 mg PO/IV once daily on days 1, 2, 8, 9, 15, 16, 22, 23, given second after bortezomib
+
**Patients at least 70 years of age, with peripheral edema or congestive heart failure (CHF) received [[Dexamethasone (Decadron)]] 20 mg PO/IV once daily on days 1, 2, 8, 9, 15, 16, 22, 23, given second after [[Bortezomib (Velcade)]]
  
−
'''4-6 week cycles x up to 20 cycles'''
+
'''4 to 6 week cycles x up to 20 cycles'''
  
 
===References===
 
===References===
Line 269: Line 266:
 
==Bortezomib (Velcade)==
 
==Bortezomib (Velcade)==
 
===Regimen #1, Reece et al. 2009 & 2011 - twice per week===
 
===Regimen #1, Reece et al. 2009 & 2011 - twice per week===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 282: Line 279:
  
 
===Regimen #2, Reece et al. 2009 & 2011 - weekly schedule===
 
===Regimen #2, Reece et al. 2009 & 2011 - weekly schedule===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 295: Line 292:
  
 
===References===
 
===References===
−
# Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL; VELCADE CAN2007 Study Group. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009 Aug 20;114(8):1489-97. doi: 10.1182/blood-2009-02-203398. Epub 2009 Jun 4. [http://bloodjournal.hematologylibrary.org/content/114/8/1489.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19498019 PubMed]
+
# Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL; VELCADE CAN2007 Study Group. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009 Aug 20;114(8):1489-97. Epub 2009 Jun 4. [http://bloodjournal.hematologylibrary.org/content/114/8/1489.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19498019 PubMed]
−
# '''Retrospective:''' Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010 Feb 20;28(6):1031-7. doi: 10.1200/JCO.2009.23.8220. Epub 2010 Jan 19. [http://jco.ascopubs.org/content/28/6/1031.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/20085941 PubMed]
+
# '''Retrospective:''' Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010 Feb 20;28(6):1031-7. Epub 2010 Jan 19. [http://jco.ascopubs.org/content/28/6/1031.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/20085941 PubMed]
−
# Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011 Jul 28;118(4):865-73. doi: 10.1182/blood-2011-02-334227. Epub 2011 May 11. [http://bloodjournal.hematologylibrary.org/content/118/4/865.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21562045 PubMed]
+
# Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011 Jul 28;118(4):865-73. Epub 2011 May 11. [http://bloodjournal.hematologylibrary.org/content/118/4/865.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21562045 PubMed]
  
 
==CRD==
 
==CRD==
Line 303: Line 300:
  
 
===Regimen===
 
===Regimen===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 315: Line 312:
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1, 8, 15, 22
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1, 8, 15, 22
 
**In Palladini et al. 2013 only, patients who retained over 3% body weight despite "optimal diuretic use" received [[Dexamethasone (Decadron)]] 20 mg PO once per week
 
**In Palladini et al. 2013 only, patients who retained over 3% body weight despite "optimal diuretic use" received [[Dexamethasone (Decadron)]] 20 mg PO once per week
−
 
−
'''28-day cycles x up to 9 cycles or 2 years, depending on reference'''
 
  
 
Supportive medications (varies depending on reference):
 
Supportive medications (varies depending on reference):
Line 322: Line 317:
 
*In Kumar et al. 2012, patients with previous thrombotic histories or who were considered to be higher thrombotic risks were recommended to receive low molecular weight heparin or [[Warfarin (Coumadin)]]
 
*In Kumar et al. 2012, patients with previous thrombotic histories or who were considered to be higher thrombotic risks were recommended to receive low molecular weight heparin or [[Warfarin (Coumadin)]]
 
*Kumar et al. 2012: "Routine antibiotic, antiviral, or antifungal prophylaxis was not mandated and left to the discretion of the treating physician."
 
*Kumar et al. 2012: "Routine antibiotic, antiviral, or antifungal prophylaxis was not mandated and left to the discretion of the treating physician."
 +
 +
'''28-day cycles x up to 9 cycles or 2 years, depending on reference'''
  
 
===References===
 
===References===
−
# Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24;119(21):4860-7. doi: 10.1182/blood-2012-01-407791. Epub 2012 Apr 13. [http://bloodjournal.hematologylibrary.org/content/119/21/4860.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22504925 PubMed]
+
# Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24;119(21):4860-7. Epub 2012 Apr 13. [http://bloodjournal.hematologylibrary.org/content/119/21/4860.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22504925 PubMed]
−
# Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M, Perlini S, Merlini G. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica. 2013 Mar;98(3):433-6. doi: 10.3324/haematol.2012.073593. Epub 2012 Sep 14. [http://www.haematologica.org/content/98/3/433.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22983583 PubMed]
+
# Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M, Perlini S, Merlini G. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica. 2013 Mar;98(3):433-6. Epub 2012 Sep 14. [http://www.haematologica.org/content/98/3/433.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22983583 PubMed]
  
 
==CTD==
 
==CTD==
Line 331: Line 328:
  
 
===Regimen #1, Wechalekar et al. 2007===
 
===Regimen #1, Wechalekar et al. 2007===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 342: Line 339:
 
*[[Thalidomide (Thalomid)]] 100 mg PO once daily on days 1 to 21, then increased to 200 mg PO once daily on days 1 to 21 if well tolerated after 4 weeks
 
*[[Thalidomide (Thalomid)]] 100 mg PO once daily on days 1 to 21, then increased to 200 mg PO once daily on days 1 to 21 if well tolerated after 4 weeks
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1 to 4, 9 to 12
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1 to 4, 9 to 12
−
 
−
'''21-day cycles, "given until a stable clonal response was achieved on consecutive samples at least 4 weeks apart" or until confirmed lack of response'''
 
  
 
Supportive medications:
 
Supportive medications:
 
*"Antimicrobial and thromboprophylaxis were given according to local protocol"; no routine thromboprophylaxis
 
*"Antimicrobial and thromboprophylaxis were given according to local protocol"; no routine thromboprophylaxis
 +
 +
'''21-day cycles, "given until a stable clonal response was achieved on consecutive samples at least 4 weeks apart" or until confirmed lack of response'''
  
 
===Regimen #2, Wechalekar et al. 2007 - risk attenuated regimen===
 
===Regimen #2, Wechalekar et al. 2007 - risk attenuated regimen===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 361: Line 358:
 
*[[Thalidomide (Thalomid)]] 50 mg PO once daily on days 1 to 28, increased by 50 mg every 4 weeks as tolerated to a maximum dose of 200 mg PO once daily
 
*[[Thalidomide (Thalomid)]] 50 mg PO once daily on days 1 to 28, increased by 50 mg every 4 weeks as tolerated to a maximum dose of 200 mg PO once daily
 
*[[Dexamethasone (Decadron)]] 20 mg PO once daily on days 1 to 4, 15 to 18
 
*[[Dexamethasone (Decadron)]] 20 mg PO once daily on days 1 to 4, 15 to 18
−
 
−
'''28-day cycles, "given until a stable clonal response was achieved on consecutive samples at least 4 weeks apart" or until confirmed lack of response'''
 
  
 
Supportive medications:
 
Supportive medications:
 
*"Antimicrobial and thromboprophylaxis were given according to local protocol"; no routine thromboprophylaxis
 
*"Antimicrobial and thromboprophylaxis were given according to local protocol"; no routine thromboprophylaxis
 +
 +
'''28-day cycles, "given until a stable clonal response was achieved on consecutive samples at least 4 weeks apart" or until confirmed lack of response'''
  
 
===References===
 
===References===
Line 373: Line 370:
  
 
===Regimen #1, Sanchorwala et al. 2007===
 
===Regimen #1, Sanchorwala et al. 2007===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 380: Line 377:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
 +
 +
''The trial used an initial lenalidomide dose of 25 mg PO once daily, but it was reduced to 15 mg because 25 mg was poorly tolerated.''
  
 
*[[Lenalidomide (Revlimid)]] 15 mg PO once daily on days 1 to 21
 
*[[Lenalidomide (Revlimid)]] 15 mg PO once daily on days 1 to 21
−
**The trial used an initial dose of 25 mg PO once daily, but it was reduced to 15 mg because 25 mg was poorly tolerated.
 
  
−
'''28-day cycles; if no response after 3 cycles of therapy, then patients would receive:'''
+
'''28-day cycles; if no response after 3 cycles of therapy, then patients would also receive:'''
  
−
*[[Lenalidomide (Revlimid)]] 15 mg PO once daily on days 1 to 21, given every cycle
 
 
*[[Dexamethasone (Decadron)]] 10 to 20 mg PO once daily on days 1 to 4, 9 to 12, 17 to 20, given every other cycle
 
*[[Dexamethasone (Decadron)]] 10 to 20 mg PO once daily on days 1 to 4, 9 to 12, 17 to 20, given every other cycle
−
 
−
'''28-day cycles, given until progression of disease or unacceptable toxicity'''
 
  
 
Supportive medications:
 
Supportive medications:
 
*[[Aspirin]] 81 or 325 mg (physician discretion) PO once daily as prophylaxis
 
*[[Aspirin]] 81 or 325 mg (physician discretion) PO once daily as prophylaxis
−
*Proton pump inhibitor used for patients receiving dexamethasone
+
*Proton pump inhibitor used for patients receiving [[Dexamethasone (Decadron)]]
 +
 
 +
'''28-day cycles, given until progression of disease or unacceptable toxicity'''
  
 
===Regimen #2, Dispenzieri et al. 2007===
 
===Regimen #2, Dispenzieri et al. 2007===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 406: Line 403:
 
*[[Lenalidomide (Revlimid)]] 25 mg PO once daily on days 1 to 21
 
*[[Lenalidomide (Revlimid)]] 25 mg PO once daily on days 1 to 21
  
−
'''28-day cycles; if no response after 3 cycles of therapy, then patients would receive:'''
+
'''28-day cycles; if no response after 3 cycles of therapy, then patients would also receive:'''
  
−
*[[Lenalidomide (Revlimid)]] 25 mg PO once daily on days 1 to 21
 
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1 to 4, 15 to 18
 
*[[Dexamethasone (Decadron)]] 40 mg PO once daily on days 1 to 4, 15 to 18
  
 
'''28-day cycles with target 12 total cycles, could continue if response observed'''
 
'''28-day cycles with target 12 total cycles, could continue if response observed'''
−
 
−
Supportive medications: not specified
 
  
 
===References===
 
===References===
Line 421: Line 415:
 
==Pomalidomide (Pomalyst)==
 
==Pomalidomide (Pomalyst)==
 
===Regimen===
 
===Regimen===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 432: Line 426:
 
**See Dispenzieri et al. 2012 for dose escalations and reductions
 
**See Dispenzieri et al. 2012 for dose escalations and reductions
 
*[[Dexamethasone (Decadron)]] 40 mg PO once per week
 
*[[Dexamethasone (Decadron)]] 40 mg PO once per week
−
 
−
'''28-day cycles, given until progression of disease'''
 
  
 
Supportive medications:
 
Supportive medications:
 
*[[Aspirin]] 325 mg PO once daily for thromboprophylaxis
 
*[[Aspirin]] 325 mg PO once daily for thromboprophylaxis
 +
 +
'''28-day cycles, given until progression of disease'''
  
 
===References===
 
===References===
−
# Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012 Jun 7;119(23):5397-404. doi: 10.1182/blood-2012-02-413161. Epub 2012 Apr 4. [http://bloodjournal.hematologylibrary.org/content/119/23/5397.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22493299 PubMed]
+
# Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012 Jun 7;119(23):5397-404. Epub 2012 Apr 4. [http://bloodjournal.hematologylibrary.org/content/119/23/5397.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22493299 PubMed]
  
 
==RdC==
 
==RdC==
Line 445: Line 439:
  
 
===Regimen===
 
===Regimen===
−
Level of Evidence:
+
 
 
<span  
 
<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
Line 455: Line 449:
 
''This was the highest dose level tested in Kastritis et al. 2012, which had no dose-limiting toxicities.''
 
''This was the highest dose level tested in Kastritis et al. 2012, which had no dose-limiting toxicities.''
 
*[[Lenalidomide (Revlimid)]] 15 mg PO once daily on days 1 to 21
 
*[[Lenalidomide (Revlimid)]] 15 mg PO once daily on days 1 to 21
 +
*[[Dexamethasone (Decadron)]] 20 mg PO once daily on days 1 to 4
 
*[[Cyclophosphamide (Cytoxan)]] 100 mg PO once daily on days 1 to 10
 
*[[Cyclophosphamide (Cytoxan)]] 100 mg PO once daily on days 1 to 10
−
*[[Dexamethasone (Decadron)]] 20 mg PO once daily on days 1 to 4
 
−
 
−
'''28-day cycles x 12 cycles'''
 
  
 
Supportive medications:
 
Supportive medications:
Line 465: Line 457:
 
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim-sulfamethoxazole (Bactrim)]], dose and schedule not listed
 
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim-sulfamethoxazole (Bactrim)]], dose and schedule not listed
 
*[[Valacyclovir (Valtrex)]], dose and schedule not listed
 
*[[Valacyclovir (Valtrex)]], dose and schedule not listed
 +
 +
'''28-day cycles x 12 cycles'''
  
 
===References===
 
===References===
−
# Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S, Dimopoulos MA. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012 Jun 7;119(23):5384-90. doi: 10.1182/blood-2011-12-396903. Epub 2012 Apr 18. [http://bloodjournal.hematologylibrary.org/content/119/23/5384.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22517904 PubMed]
+
# Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S, Dimopoulos MA. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012 Jun 7;119(23):5384-90. Epub 2012 Apr 18. [http://bloodjournal.hematologylibrary.org/content/119/23/5384.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22517904 PubMed]

Revision as of 04:55, 19 November 2013

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.


Untreated (including transplant ineligible)

CRD

CRD: Cyclophosphamide, Revlimid, Dexamethasone

Regimen, Kumar et al. 2012

Phase II

Supportive medications:

  • Aspirin 81, 100, or 325 mg PO once daily for thromboprophylaxis
  • Patients with previous thrombotic histories or who were considered to be higher thrombotic risks were recommended to receive low molecular weight heparin or Warfarin (Coumadin)
  • "Routine antibiotic, antiviral, or antifungal prophylaxis was not mandated and left to the discretion of the treating physician."

28-day cycles x up to 2 years

References

  1. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24;119(21):4860-7. Epub 2012 Apr 13. link to original article contains verified protocol PubMed

CTD

CTD: Cyclophosphamide, Thalidomide, Dexamethasone

Regimen #1, Wechalekar et al. 2007

Phase II

Supportive medications:

  • "Antimicrobial and thromboprophylaxis were given according to local protocol"; no routine thromboprophylaxis

21-day cycles, "given until a stable clonal response was achieved on consecutive samples at least 4 weeks apart" or until confirmed lack of response

Regimen #2, Wechalekar et al. 2007 - risk attenuated regimen

Phase II

For elderly patients (age >70 years), NYHA heart failure >class II, and those with significant fluid overload.

Supportive medications:

  • "Antimicrobial and thromboprophylaxis were given according to local protocol"; no routine thromboprophylaxis

28-day cycles, "given until a stable clonal response was achieved on consecutive samples at least 4 weeks apart" or until confirmed lack of response

References

  1. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007 Jan 15;109(2):457-64. Epub 2006 Sep 21. link to original article contains verified protocol PubMed

CyBorD

CyBorD: Cyclophosphamide, Bortezomib, Dexamethasone

Regimen

Phase II, <20 patients reported

Supportive medications:

  • "Antiviral prophylaxis"

28-day cycles x 2 to 6 cycles

References

  1. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012 May 10;119(19):4391-4. Epub 2012 Feb 13. link to original article contains verified protocol PubMed

Lenalidomide +/- Dexamethasone

Regimen #1, Sanchorwala et al. 2007

Phase II

The trial used an initial dose of lenalidomide of 25 mg PO once daily, but it was reduced to 15 mg because 25 mg was poorly tolerated.

28-day cycles; if no response after 3 cycles of therapy, then patients would also receive:

Supportive medications:

  • Aspirin 81 or 325 mg (physician discretion) PO once daily as prophylaxis
  • Proton pump inhibitor used for patients receiving dexamethasone

28-day cycles, given until progression of disease or unacceptable toxicity

Regimen #2, Dispenzieri et al. 2007

Phase II

28-day cycles; if no response after 3 cycles of therapy, then patients would also receive:

28-day cycles with target 12 total cycles, could continue if response observed

Supportive medications: not specified

References

  1. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, Seldin DC. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007 Jan 15;109(2):492-6. Epub 2006 Sep 7. link to original article contains verified protocol PubMed
  2. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007 Jan 15;109(2):465-70. Epub 2006 Sep 28. link to original article contains verified protocol PubMed

Melphalan & Dexamethasone

Regimen

Phase II

Supportive medications:

28-day cycles x up to 9 cycles

References

  1. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, Rustichelli R, Virga G, Merlini G. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004 Apr 15;103(8):2936-8. Epub 2003 Dec 18. link to original article contains protocol PubMed
  2. Retrospective: Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013 Apr 25;121(17):3420-7. Epub 2013 Mar 11. link to original article PubMed Melphalan & dexamethasone (MDex) only regimen explicitly mentioned in cohort. Others included thalidomide combination, bortezomib combination, and lenalidomide combination.

MRD

MRD: Melphalan, Revlimid, Dexamethasone

Regimen #1, Sanchorwala et al. 2012

Phase II, <20 patients reported

Sanchorawala et al. 2012 did not outright specify oral routes for melphalan and dexamethasone, but this is assumed based on how the paper discussed existing oral melphalan and dexamethasone regimens.

Supportive medications:

28-day cycles x 12 cycles, until progression of disease, or unacceptable toxicity

Regimen #2, Moreau et al. 2010

Phase II

To be completed

References

  1. Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, Salles G, Leblond V, Roussel M, Alakl M, Hermine O, Planche L, Harousseau JL, Fermand JP. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010 Dec 2;116(23):4777-82. Epub 2010 Aug 19. link to original article PubMed
  2. Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica. 2013 May;98(5):789-92. Epub 2012 Nov 9. link to original article contains verified protocol PubMed

RdC

RdC: Revlimid, dexamethasone, Cyclophosphamide

Regimen

Phase II

This was the highest dose level tested in Kastritis et al. 2012, which had no dose-limiting toxicities.

Supportive medications:

28-day cycles x 12 cycles

References

  1. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S, Dimopoulos MA. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012 Jun 7;119(23):5384-90. Epub 2012 Apr 18. link to original article contains verified protocol PubMed

VMD

VMD: Velcade, Melphalan, Dexamethasone

Regimen

Phase II

4 to 6 week cycles x up to 20 cycles

References

  1. Zonder JA, Sanchorawala V, Snyder RM, Matous J, Terebelo H, Janakiraman N, Mapara MY, Lalo S, Tageja N, Webb C, Monsma D, Sellers C, Abrams J, Gasparetto C. Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL Amyloidosis with Tolerable Neurotoxicity. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 746. link to abstract

Relapsed/refractory

Bortezomib (Velcade)

Regimen #1, Reece et al. 2009 & 2011 - twice per week

Phase II

21-day cycles x up to 8 cycles, with extended treatment allowed for patients with clear clinical benefit

Regimen #2, Reece et al. 2009 & 2011 - weekly schedule

Phase II

35-day cycle x up to 8 cycles, with extended treatment allowed for patients with clear clinical benefit

References

  1. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL; VELCADE CAN2007 Study Group. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009 Aug 20;114(8):1489-97. Epub 2009 Jun 4. link to original article contains verified protocol PubMed
  2. Retrospective: Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010 Feb 20;28(6):1031-7. Epub 2010 Jan 19. link to original article PubMed
  3. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011 Jul 28;118(4):865-73. Epub 2011 May 11. link to original article contains verified protocol PubMed

CRD

CRD: Cyclophosphamide, Revlimid, Dexamethasone

Regimen

Phase II

Supportive medications (varies depending on reference):

  • Aspirin 81, 100, or 325 mg PO once daily for thromboprophylaxis
  • In Kumar et al. 2012, patients with previous thrombotic histories or who were considered to be higher thrombotic risks were recommended to receive low molecular weight heparin or Warfarin (Coumadin)
  • Kumar et al. 2012: "Routine antibiotic, antiviral, or antifungal prophylaxis was not mandated and left to the discretion of the treating physician."

28-day cycles x up to 9 cycles or 2 years, depending on reference

References

  1. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24;119(21):4860-7. Epub 2012 Apr 13. link to original article contains verified protocol PubMed
  2. Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M, Perlini S, Merlini G. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica. 2013 Mar;98(3):433-6. Epub 2012 Sep 14. link to original article contains verified protocol PubMed

CTD

CTD: Cyclophosphamide, Thalidomide, Dexamethasone

Regimen #1, Wechalekar et al. 2007

Phase II

Supportive medications:

  • "Antimicrobial and thromboprophylaxis were given according to local protocol"; no routine thromboprophylaxis

21-day cycles, "given until a stable clonal response was achieved on consecutive samples at least 4 weeks apart" or until confirmed lack of response

Regimen #2, Wechalekar et al. 2007 - risk attenuated regimen

Phase II

For elderly patients (age >70 years), NYHA heart failure >class II, and those with significant fluid overload.

Supportive medications:

  • "Antimicrobial and thromboprophylaxis were given according to local protocol"; no routine thromboprophylaxis

28-day cycles, "given until a stable clonal response was achieved on consecutive samples at least 4 weeks apart" or until confirmed lack of response

References

  1. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007 Jan 15;109(2):457-64. Epub 2006 Sep 21. link to original article contains verified protocol PubMed

Lenalidomide & Dexamethasone

Regimen #1, Sanchorwala et al. 2007

Phase II

The trial used an initial lenalidomide dose of 25 mg PO once daily, but it was reduced to 15 mg because 25 mg was poorly tolerated.

28-day cycles; if no response after 3 cycles of therapy, then patients would also receive:

Supportive medications:

28-day cycles, given until progression of disease or unacceptable toxicity

Regimen #2, Dispenzieri et al. 2007

Phase II

28-day cycles; if no response after 3 cycles of therapy, then patients would also receive:

28-day cycles with target 12 total cycles, could continue if response observed

References

  1. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, Seldin DC. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007 Jan 15;109(2):492-6. Epub 2006 Sep 7. link to original article contains verified protocol PubMed
  2. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007 Jan 15;109(2):465-70. Epub 2006 Sep 28. link to original article contains verified protocol PubMed

Pomalidomide (Pomalyst)

Regimen

Phase II

Supportive medications:

  • Aspirin 325 mg PO once daily for thromboprophylaxis

28-day cycles, given until progression of disease

References

  1. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012 Jun 7;119(23):5397-404. Epub 2012 Apr 4. link to original article contains verified protocol PubMed

RdC

RdC: Revlimid, dexamethasone, Cyclophosphamide

Regimen

Phase II

This was the highest dose level tested in Kastritis et al. 2012, which had no dose-limiting toxicities.

Supportive medications:

28-day cycles x 12 cycles

References

  1. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S, Dimopoulos MA. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012 Jun 7;119(23):5384-90. Epub 2012 Apr 18. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Light-chain_(AL)_amyloidosis&oldid=4058"